Sertraline
A double-blind placebo RCT assessed if oral sertraline (50 mg/day) can
contribute to preserving the hearing threshold among patients with
lymphoma and gastric cancer exposed to cisplatin. The two groups were
distributed homogeneously. The ototoxicity grade for the sertraline
group was lower compared to the placebo group (p<0.001). The
level of distortion product otoacoustic emissions was unchanged among
57.1% in the sertraline group versus 17.1% in the placebo group
(p=0.000). However, 11.4% of the patients in the sertraline group
reported severe nausea and vomiting (Delarestaghi et al., 2018).